Yahoo
OTC Markets OTCQX - Delayed Quote USD

Bayer Aktiengesellschaft (BAYRY)

13.95 -0.04 (-0.29%)
At close: November 2 at 3:59:59 PM EST
BAYRY Q3 2026 earnings call
Today at 8 AM EST
Chart Range Bar
Loading chart for BAYRY
  • Previous Close 13.99
  • Open 13.94
  • Bid 13.86 x 230000
  • Ask 14.03 x 128800
  • Day's Range 13.89 - 14.03
  • 52 Week Range 7.48 - 15.23
  • Volume 75,540
  • Avg. Volume 605,306
  • Market Cap (intraday) 54.819B
  • Beta (5Y Monthly) 0.81
  • PE Ratio (TTM) --
  • EPS (TTM) -0.51
  • Earnings Date Nov 3, 2026
  • Forward Dividend & Yield 0.03 (0.23%)
  • 1y Target Est 15.90
  • Morningstar Rating Rating available with Stock Picks access

Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment offers nonprescription over-the-counter medicines for self-medication and self-care; nutritional supplements; allergy, cough, and cold; dermatology; pain and cardiovascular risk prevention; and digestive health products. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solutions, and pest and weed management products, as well as customer services for agriculture. It also engages in the breeding, propagation, and production/processing of seeds, including seed dressing. The company distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft has a strategic alliance with The University of Colorado Anschutz, along with UCHealth and Children's Hospital Colorado to advance drug development and clinical trials. Bayer Aktiengesellschaft has a strategic alliance Henry Ford Health. It has a commercial agreement with Neste to Jointly scale newgold winter canola for biofuels production. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.

www.bayer.com

87,830

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 11/2/2026, which may include dividends or other distributions. Benchmark is DAX P (^GDAXI) .

YTD Return

BAYRY
29.43%
DAX P (^GDAXI)
6.09%

1-Year Return

BAYRY
80.54%
DAX P (^GDAXI)
8.44%

3-Year Return

BAYRY
32.79%
DAX P (^GDAXI)
71.56%

5-Year Return

BAYRY
5.41%
DAX P (^GDAXI)
62.85%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 10.87B
Earnings 219M
Profit Margin 2.01%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

0
5B
10B
-30.0%
-20.0%
-10.0%
0.0%
10.0%
20.0%

Analyst Insights

View More

Analyst Price Targets

15.30
15.90 Average
13.95 Current
16.68 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 10/1/2020
Analyst Citigroup
Rating Action Downgrade
Rating Neutral
Price Action --
Price Target --

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -3.83%

  • Return on Assets (ttm)

    3.18%

  • Return on Equity (ttm)

    -5.69%

  • Revenue (ttm)

    45.38B

  • Net Income Avi to Common (ttm)

    -1.74B

  • Diluted EPS (ttm)

    -0.51

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    5.08B

  • Total Debt/Equity (mrq)

    129.36%

  • Levered Free Cash Flow (ttm)

    6.56B

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: